ROTH Capital Partners Acts as Co-Manager
for Amarin Corporation plc (Nasdaq: AMRN)
in its $460 Million Follow-On

   

For more information please contact:

Investment Banking

James Antonopoulos
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1906
 
Eric B. Cheng
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1901
echeng@roth.com
 
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
agurewitz@roth.com
 
Nazan Akdeniz
Senior Vice President
(949) 720-5740
nakdeniz@roth.com
 
Lou Ellis
Senior Vice President
(949) 720-5739
lellis@roth.com

Transaction Information
Amarin Corporation plc (Nasdaq: AMRN) has closed an underwritten public offering of 25,555,556 American Depositary Shares ("ADSs"), which includes 3,333,333 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The ADSs were sold at the public offering price of $18.00 per ADS, resulting in the gross proceeds for Amarin of approximately $460 million.

Amarin intends to use the proceeds from the offering (1) to support the ongoing and expanding commercialization of Vascepaģ (icosapent ethyl) assuming the FDA approves Amarinís supplemental new drug application seeking an expanded indication for Vascepa in the United States based on the positive results of Amarinís REDUCE-ITô study, including (i) doubling the size of its existing sales force, (ii) increasing branded and non-branded advertising, and (iii) supporting its expanded commercial operations; (2) to increase commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes. Amarin also may use a portion of the proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard.

ROTH Capital Partners acted as co-manager for the offering.

About Amarin Corporation plc
Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarinís product development program leverages its extensive experience in polyunsaturated fatty acids and lipid science. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription in the United States, Lebanon and the United Arab Emirates. Amarinís commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East. For more information, please visit https://amarincorp.com. (Source: Company Press Release | 7/18/19)

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

Date of Announcement: 7/30/19

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2019.